La cadena de opciones muestra datos clave de las opciones de acciones de Alumis a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Alumis..

Alumis (NASDAQ:ALMS) Bolsa, Cadena de Opciones

ALUMIS INC

Alumis

Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.

wall street chart shutter2

News

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

ALMS

CMRX

DERM

Alumis, Chimerix y Journey Medical presentan altos valores RSI, lo que podría señalar sobrecompra. ¿Es este el momento adecuado para invertir?

¿Deberías preocuparnos por estas 3 acciones del sector salud? El RSI indica sobrecompra

Alumis Inc

<a href="https://www.axios.com/2025/06/02/iran-nuclear-deal-proposal-enrich-uranium">https://www.axios.com/2025/06/02/iran-nuclear-deal-proposal-enrich-uranium</a>

General

'U.S. nuclear deal offer allows Iran to enrich uranium'- Axios

<ul>
<li>Two new partnerships enhance QIAGEN's capabilities to support pharma partner clinical trials with significant expansion of MRD capabilities – especially using QIAcuity digital PCR</li>
<li>Tracer Biotechnologies partnership to develop blood-based minimal residual disease (MRD) tests on QIAcuity digital PCR systems for solid cancer tumors</li>
<li>Collaboration with Foresight Diagnostics aims to develop a kit version of its CLARITY&#x2122; NGS assay for use in lymphoma</li>
</ul>
QIAGEN (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>, Frankfurt Prime Standard: QIA))) today announced the expansion of its oncology diagnostics portfolio with two strategic partnerships to advance the use of minimal residual disease (MRD) testing in clinical trials to support pharma co-development projects for companion diagnostics. The new collaborations with Tracer Biotechnologies and Foresight Diagnostics expand QIAGEN's reach in MRD testing and cover solid tumors and hematological cancers.
Minimal residual disease (MRD) testing is becoming a cornerstone of oncology by enabling early detection of cancer recurrence and guiding timely adjustments to therapy from a blood sample. These new partnerships support the growing demand for decentralized, non-invasive tools that advance precision medicine and help deliver more personalized care.
Under the new collaborations:
<ul>
<li>Tracer Biotechnologies, a developer of blood-based molecular diagnostics for cancer, is working with QIAGEN to create companion diagnostics for MRD testing in solid tumors. These assays, designed for use on QIAGEN's QIAcuity digital PCR platform, are designed to enable the use of minimally invasive blood samples to monitor residual disease with high sensitivity. The approach offers a cost-efficient and quick way to support decentralized implementation in clinical laboratories with results comparable to those generated using next-generation sequencing technologies.</li>
<li>Foresight Diagnostics and QIAGEN are creating a kit-based version of the Foresight CLARITY&#x2122; assay, a circulating tumor DNA (ctDNA)-based NGS test for certain types of lymphoma. Transitioning the assay from a CLIA central laboratory service to an in-lab kit is designed to allow for broader clinical access and supports pharmaceutical-sponsored trials with companion diagnostic applications.</li>
</ul>
MRD testing offers a highly sensitive way to monitor treatment response, identify patients at risk of relapse before symptoms appear and inform decisions on therapy usage. It is also emerging as a surrogate endpoint in clinical trials, accelerating drug development and regulatory review.
QIAGEN's MRD portfolio spans sample technologies and testing platforms that support workflows from sample to insight. This includes the QIAsymphony system for automated sample preparation, with the new generation QIAsymphony Connect upgraded version being prepared for launch in late 2025, along with PAXgene blood collection tubes for stabilized blood draws. QIAGEN also offers an extensive range of kits for use on the QIAcuity family of digital PCR instruments as well as the QIAseq targeted gene panels for use on third-party NGS systems. Complementing these solutions is the portfolio of QIAGEN Digital Insights solutions that offer integrated bioinformatics for comprehensive NGS data analysis and interpretation to enable comprehensive MRD results.

QGEN

QIAGEN Expands Oncology Diagnostics Portfolio With Two Strategic Partnerships To Advance Use Of MRD Testing In Clinical Trials To Support Pharma Co-Development Projects For Companion Diagnostics

IBKR

Interactive Brokers Group Reports 3.384M Daily Average Revenue Trades In May, Up 43% From Last Year And 11% Lower Than Prior Month

Mullen Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) shares are trading lower Monday after the company announced it acquired an <a href="https://www.benzinga.com/pressreleases/25/06/g45724986/mullen-reaches-definitive-agreement-to-acquire-additional-21-of-bollinger-motors-bringing-its-tota">additional 21% of Bollinger Motors</a>.
What To Know: The additional stake brings the company&#8217;s total ownership in Bollinger to 95% and boosts shareholder equity by approximately $3.5 million.
&#8220;This is an important moment for both Mullen Automotive and Bollinger Motors,&#8221; said David Michery, CEO and chairman of Mullen Automotive and Bollinger Motors. &#8220;Our investment in acquiring the vast majority of remaining shares and resolving certain significant outstanding debt demonstrates our belief in and continued commitment to Bollinger&#8217;s vehicle lineup and future.&#8221;
Bollinger will continue developing and producing the B4 platform, its all-electric Class 4 commercial truck, leveraging Mullen's resources and expertise to accelerate progress and integrate into Mullen's broader EV ecosystem. Mullen may be facing selling pressure as the company had just $2.3 million in cash, cash equivalents and restricted cash as of March 31. 
Mullen also began trading on a split-adjusted basis on Monday after its 1-for-100 reverse stock split went into effect. The <a href="https://www.benzinga.com/news/stock-split/25/05/45679654/mullen-automotive-stock-is-tumbling-thursday-whats-driving-the-action">reverse stock split</a> was intended to bring the company into compliance with the Nasdaq's minimum bid listing requirements of $1 per share.
Related Link: <a href="https://www.benzinga.com/news/health-care/25/06/45724030/kymera-therapeutics-says-atopic-dermatitis-potential-matches-sanofi-regenerons-blockbuster-dupixent-in-early-biomarker-response">Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron&#8217;s Blockbuster Dupixent In Early Biomarker Response</a>
MULN Price Action: At the time of publication, Mullen shares were down 30.07% at $5.74, according to data from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Image: courtesy of Mullen Automotive.

Movers

MULN

Mullen Automotive Stock Is Falling Monday: What's Going On?

Circle Internet Financial is pushing forward with its public listing plans, now targeting a valuation of $7.2 billion as it gears up for an <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45622634/usdc-issuer-circle-eyes-600m-raise-in-nyse-ipo-targets-5-4b-valuation">initial public offering</a>.
What Happened: The company <a href="https://www.theblock.co/post/356602/circle-seeks-7-2-billion-valuation-in-upsized-ipo?utm_source=twitter&amp;utm_medium=social">announced</a> an increased offering size, reflecting heightened investor interest, with expectations of raising as much as $896 million through the sale of 32 million shares.
Originally, Circle intended to offer 24 million shares priced between $24 and $26. 
However, revised filings indicate the firm now aims to price its stock at $27 to $28 per share. 
This valuation remains below the $9 billion mark it was set to achieve in a previously abandoned SPAC deal in 2022. 
Despite this, major institutional players, most notably BlackRock (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NASDAQ">BLK</a>), are said to be backing the IPO.
Circle, best known as the issuer behind USD Coin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDC</a>), the world's second-largest stablecoin, has seen growing financial strength, especially through returns on U.S. Treasury holdings. 
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45727395/tom-lee-predicts-bitcoin-to-hit-250000-by-end-of-2025-3m-long-term">Tom Lee Predicts Bitcoin To Hit $250,000 By End Of 2025, $3M Long Term</a>
Why It Matters: In the first quarter of 2025 alone, Circle earned over $557 million from these assets, a 55% jump compared to previous periods.
Although it trails rival Tether (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDT</a>) in revenue, Circle has benefited from rising global interest in stablecoins, bolstered by clearer regulatory frameworks and increased real-world adoption. 
According to Standard Chartered, the market cap for stablecoins could expand tenfold by 2028. Similarly, a recent Artemis survey revealed that business-to-business stablecoin usage now accounts for the majority of stablecoin transaction volumes.
The company has secured approval to list on the New York Stock Exchange under the ticker symbol "CRCL," though a final listing date has yet to be confirmed. 
Plans to debut by April were delayed due to market instability tied to U.S. tariff policy debates. 
Despite reports of acquisition interest from Coinbase (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">COIN</a>) and Ripple (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>), Circle has publicly denied pursuing any merger or acquisition deals at this time.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45722106/strategy-and-metaplanet-deepen-bitcoin-exposure-with-over-190-million-in-fresh-buys-amid-105k-market-level">Strategy And Metaplanet Deepen Bitcoin Exposure With Over $190 Million In Fresh Buys Amid $105K Market Level</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$COIN

$USDC

$USDT

$XRP

USDC Issuer Circle Aims For $7.2B Initial Public Offering Valuation

Zai Lab Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZLAB#NASDAQ">ZLAB</a>) and NovoCure Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>) revealed additional data on Saturday from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer.
The data were presented at <a href="https://www.benzinga.com/general/health-care">the 2025 American Society of Clinical Oncology Annual Meeting</a>.
The Phase 3 PANOVA-3 trial evaluated the use of TTFields therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma compared to gemcitabine <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45710803/zai-lab-and-novocure-announce-results-from-the-phase-3-panova-3-trial-of-tumor-treating-fields-ttf" rel="noreferrer noopener">and nab-paclitaxel alone</a>.
Also Read: <a href="https://www.benzinga.com/general/biotech/25/04/44988107/novocure-warns-of-potential-11-million-tariff-hit-if-us-trade-pause-expires-in-2025" target="_blank" rel="noreferrer noopener">NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025</a>
The trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival (mOS) for patients <a href="https://www.benzinga.com/24/12/42268730/novocures-recently-approved-tumor-treating-electric-fields-shows-promise-in-pancreatic-cancer-patients" target="_blank" rel="noreferrer noopener">treated with TTFields</a>.
In the intent-to-treat population, patients treated with TTFields therapy concomitantly with gemcitabine and nab-paclitaxel had an mOS of 16.2 months compared to 14.2 months for patients treated with gemcitabine and nab-paclitaxel alone, a statistically significant 2.0-month improvement.
TTFields therapy concomitant with gemcitabine and nab-paclitaxel demonstrated improvement in several secondary endpoints, including one-year and pain-free survival rates.
The one-year survival rate showed a statistically significant improvement in the TTFields concomitant with gemcitabine and nab-paclitaxel treated group, 68.1%, compared to 60.2% for those who received gemcitabine and nab-paclitaxel alone.
Patients treated with TTFields concomitant with gemcitabine and nab-paclitaxel had a median pain-free survival of 15.2 months compared to a median of 9.1 months in the group treated with gemcitabine and nab-paclitaxel alone.
This is a statistically significant 6.1-month extension in pain-free survival. Pain-free survival was defined as the time from baseline until patients reported an increase of 20 or more points on a visual scale for pain or until death.
There was no statistically significant difference in additional secondary outcome measures of progression-free survival, local progression-free survival, objective response rate, puncture-free survival, or tumor resectability rate between the TTFields with gemcitabine and nab-paclitaxel and the gemcitabine and nab-paclitaxel arms.
TTFields therapy was well-tolerated, no new safety signals were observed, and safety was consistent with prior clinical studies. Mild to moderate skin adverse events (AEs) were the most common device-related AEs.
Price Action: NVCR stock is trading lower by 8.63% to $17.46 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45726138/dell-stock-falls-as-trump-administration-expands-spending-review-to-tech-contracts" target="_blank" rel="noreferrer noopener">Dell Stock Falls As Trump Administration Expands Spending Review To Tech Contracts</a></li>
</ul>
Photo by Aunt Spray via Shutterstock

Biotech

Health Care

NVCR

ZLAB

NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial

Morgan Stanley analyst Adrienne Yih maintains American Eagle Outfitters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEO#NYSE">AEO</a>) with a Equal-Weight and lowers the price target from $11 to $10.

Price Target

Analyst Ratings

Morgan Stanley Maintains Equal-Weight on American Eagle Outfitters, Lowers Price Target to $10

Providing a diverse range of perspectives from bullish to bearish, 9 analysts have published ratings on Harmony Biosciences Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRMY#NASDAQ">HRMY</a>) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $52.11, a high estimate of $70.00, and a low estimate of $44.00. This current average has increased by 1.94% from the previous average price target of $51.12. 
<img src="https://www.benzinga.com/files/images/story/2025/1748887265_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive Harmony Biosciences Hldgs is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andreas Argyrides</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$61.00</td>
<td>-</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$48.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$49.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$49.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$48.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$44.00</td>
<td>$42.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Harmony Biosciences Hldgs. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Harmony Biosciences Hldgs compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Harmony Biosciences Hldgs's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Harmony Biosciences Hldgs's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HRMY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Harmony Biosciences Hldgs analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Harmony Biosciences Hldgs</h2>
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
<h3>Harmony Biosciences Hldgs: Financial Performance Dissected</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Harmony Biosciences Hldgs's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 19.48% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Harmony Biosciences Hldgs's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 24.66% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Harmony Biosciences Hldgs's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 6.6%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Harmony Biosciences Hldgs's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.43% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Harmony Biosciences Hldgs's debt-to-equity ratio is below the industry average. With a ratio of 0.24, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HRMY

Where Harmony Biosciences Hldgs Stands With Analysts

Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $307.44, a high estimate of $326.00, and a low estimate of $273.00. Witnessing a positive shift, the current average has risen by 3.69% from the previous average price target of $296.50.
<img src="https://www.benzinga.com/files/images/story/2025/1748887257_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Humana. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$273.00</td>
<td>$322.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$305.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$290.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$310.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$300.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$322.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$325.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Jason Cassorla</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Buy</td>
<td>$326.00</td>
<td>-</td>
</tr>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$316.00</td>
<td>$305.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Humana. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Humana compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Humana's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Humana's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HUM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Humana analyst ratings.</a>
<h2>Delving into Humana's Background</h2>
Humana is one of the largest private health insurers in the US, and the firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from Medicare, Medicaid, and the military's Tricare program. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
<h3>Humana: Delving into Financials</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining Humana's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 8.45% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Humana's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 3.87%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 7.29%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Humana's ROA stands out, surpassing industry averages. With an impressive ROA of 2.55%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Humana's debt-to-equity ratio is below the industry average. With a ratio of 0.75, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 9 Analyst Projections For Humana

Ratings for CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $78.4, a high estimate of $84.00, and a low estimate of $71.00. Surpassing the previous average price target of $72.30, the current average has increased by 8.44%.
<img src="https://www.benzinga.com/files/images/story/2025/1748887249_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive CVS Health. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$79.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$84.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$84.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$81.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$71.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$82.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$71.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$82.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$76.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$74.00</td>
<td>$72.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to CVS Health. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of CVS Health compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for CVS Health's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of CVS Health's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CVS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on CVS Health analyst ratings.</a>
<h2>All You Need to Know About CVS Health</h2>
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the US. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 27 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all existing business lines.
<h3>CVS Health: Financial Performance Dissected</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: CVS Health's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 6.96%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: CVS Health's net margin is impressive, surpassing industry averages. With a net margin of 1.88%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): CVS Health's ROE stands out, surpassing industry averages. With an impressive ROE of 2.33%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.7%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a high debt-to-equity ratio of 1.06, CVS Health faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 10 Analyst Ratings Have To Say About CVS Health

Whales with a lot of money to spend have taken a noticeably bullish stance on PayPal Holdings.
Looking at options history for PayPal Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) we detected 17 trades.
If we consider the specifics of each trade, it is accurate to state that 47% of the investors opened trades with bullish expectations and 47% with bearish.
From the overall spotted trades, 10 are puts, for a total amount of $476,607 and 7, calls, for a total amount of $311,493.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $47.5 to $75.0 for PayPal Holdings over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of PayPal Holdings stands at 3880.47, with a total volume reaching 4,632.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in PayPal Holdings, situated within the strike price corridor from $47.5 to $75.0, throughout the last 30 days.
<h3>PayPal Holdings Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748887246_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PYPL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$7.8</td>
<td>$7.65</td>
<td>$7.8</td>
<td>$70.00</td>
<td>$178.6K</td>
<td>1.2K</td>
<td align="right">229</td>
</tr>
<tr>
<td>PYPL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$26.4</td>
<td>$25.45</td>
<td>$26.4</td>
<td>$47.50</td>
<td>$71.2K</td>
<td>20</td>
<td align="right">28</td>
</tr>
<tr>
<td>PYPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$4.7</td>
<td>$4.55</td>
<td>$4.7</td>
<td>$70.00</td>
<td>$54.0K</td>
<td>1.3K</td>
<td align="right">6</td>
</tr>
<tr>
<td>PYPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$1.79</td>
<td>$1.53</td>
<td>$1.77</td>
<td>$72.50</td>
<td>$50.4K</td>
<td>2.0K</td>
<td align="right">292</td>
</tr>
<tr>
<td>PYPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$6.75</td>
<td>$6.65</td>
<td>$6.75</td>
<td>$67.50</td>
<td>$47.2K</td>
<td>1.3K</td>
<td align="right">63</td>
</tr>
</tbody>
</table>

<h3>About PayPal Holdings</h3>
PayPal was spun off from eBay in 2015 and provides electronic payment solutions to merchants and consumers, with a focus on online transactions. The company had 434 million active accounts at the end of 2024. The company also owns Venmo, a person-to-person payment platform.
<h3>Where Is PayPal Holdings Standing Right Now?</h3>
<ul>
<li>With a trading volume of 3,904,107, the price of PYPL is up by 0.16%, reaching $70.39.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 57 days from now.</li>
</ul>
<h3>What The Experts Say On PayPal Holdings</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $81.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Truist Securities downgraded its action to Sell with a price target of $68. 
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Buy rating on PayPal Holdings with a target price of $95. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest PayPal Holdings options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

PYPL

Spotlight on PayPal Holdings: Analyzing the Surge in Options Activity

Investors with a lot of money to spend have taken a bearish stance on Dollar General (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with DG, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 15 uncommon options trades for Dollar General.
This isn't normal.
The overall sentiment of these big-money traders is split between 46% bullish and 53%, bearish.
Out of all of the special options we uncovered, 9 are puts, for a total amount of $692,454, and 6 are calls, for a total amount of $281,042.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $83.0 and $130.0 for Dollar General, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Dollar General stands at 869.08, with a total volume reaching 8,181.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Dollar General, situated within the strike price corridor from $83.0 to $130.0, throughout the last 30 days.
<h3>Dollar General Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748887240_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DG</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$13.3</td>
<td>$13.0</td>
<td>$13.0</td>
<td>$95.00</td>
<td>$260.0K</td>
<td>76</td>
<td>200</td>
</tr>
<tr>
<td>DG</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/13/25</td>
<td>$3.05</td>
<td>$2.77</td>
<td>$3.05</td>
<td>$93.00</td>
<td>$202.5K</td>
<td>3</td>
<td>3.2K</td>
</tr>
<tr>
<td>DG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/06/25</td>
<td>$1.69</td>
<td>$1.63</td>
<td>$1.64</td>
<td>$105.00</td>
<td>$128.6K</td>
<td>1.1K</td>
<td>1.2K</td>
</tr>
<tr>
<td>DG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/06/25</td>
<td>$3.15</td>
<td>$3.0</td>
<td>$3.04</td>
<td>$95.00</td>
<td>$45.6K</td>
<td>1.7K</td>
<td>161</td>
</tr>
<tr>
<td>DG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/06/25</td>
<td>$1.19</td>
<td>$1.06</td>
<td>$1.19</td>
<td>$107.00</td>
<td>$35.7K</td>
<td>2.1K</td>
<td>352</td>
</tr>
</tbody>
</table>

<h3>About Dollar General</h3>
With more than 20,000 locations, Dollar General's banner is nearly ubiquitous across the rural United States. Dollar General serves as a convenient shopping destination for fill-in store trips, with its value proposition most relevant to consumers in small communities with a dearth of shopping options. The retailer operates a frugal store of about 7,500 square feet and primarily offers an assortment of branded and private-label consumable items (80% of net sales) such as paper and cleaning products, packaged food, and health and beauty items at low prices. Dollar General also offers a limited assortment of seasonal merchandise, home products, and apparel. The firm sells most items at a price point of $10 or less.
Having examined the options trading patterns of Dollar General, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Dollar General</h3>
<ul>
<li>With a trading volume of 1,979,832, the price of DG is up by 0.23%, reaching $97.47.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 1 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Dollar General</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $104.2.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Morgan Stanley persists with their Equal-Weight rating on Dollar General, maintaining a target price of $85. 
&#x2A; Consistent in their evaluation, an analyst from Goldman Sachs keeps a Buy rating on Dollar General with a target price of $96. 
&#x2A; Consistent in their evaluation, an analyst from Guggenheim keeps a Buy rating on Dollar General with a target price of $105. 
&#x2A; An analyst from B of A Securities persists with their Buy rating on Dollar General, maintaining a target price of $115. 
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Buy rating on Dollar General with a target price of $120. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Dollar General with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Looking At Dollar General's Recent Unusual Options Activity

Welltower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Welltower, revealing an average target of $163.43, a high estimate of $175.00, and a low estimate of $157.00. This current average has increased by 7.73% from the previous average price target of $151.71. 
<img src="https://www.benzinga.com/files/images/story/2025/1748887239_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Welltower. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Kilichowski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$175.00</td>
<td>$158.00</td>
</tr>
<tr>
<td>Ronald Kamdem</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$157.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>John Kilichowski</td>
<td>Wells Fargo</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$158.00</td>
<td>$158.00</td>
</tr>
<tr>
<td>Omotayo Okusanya</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$170.00</td>
<td>$141.00</td>
</tr>
<tr>
<td>John Kilichowski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$158.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$166.00</td>
<td>$165.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Welltower. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Welltower compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Welltower's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Welltower's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/WELL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Welltower analyst ratings.</a>
<h2>Delving into Welltower's Background</h2>
Welltower owns a diversified healthcare portfolio of 2,336 in-place properties spread across the senior housing, medical office, and skilled nursing/postacute care sectors. The portfolio includes over 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to that of the United States.
<h3>Welltower's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Over the 3M period, Welltower showcased positive performance, achieving a revenue growth rate of 30.48% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Real Estate sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Welltower's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 10.8%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Welltower's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 0.78%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Welltower's ROA excels beyond industry benchmarks, reaching 0.49%. This signifies efficient management of assets and strong financial health.
Debt Management: Welltower's debt-to-equity ratio is below the industry average. With a ratio of 0.5, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

WELL

Forecasting The Future: 7 Analyst Projections For Welltower

Deep-pocketed investors have adopted a bearish approach towards Okta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in OKTA usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for Okta. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 40% leaning bullish and 60% bearish. Among these notable options, 4 are puts, totaling $268,616, and 6 are calls, amounting to $215,612.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $75.0 to $120.0 for Okta over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Okta's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Okta's substantial trades, within a strike price spectrum from $75.0 to $120.0 over the preceding 30 days.
<h3>Okta Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748887235_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>OKTA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$14.6</td>
<td>$14.45</td>
<td>$14.45</td>
<td>$100.00</td>
<td>$88.1K</td>
<td>39</td>
<td align="right">62</td>
</tr>
<tr>
<td>OKTA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/18/26</td>
<td>$6.6</td>
<td>$6.45</td>
<td>$6.45</td>
<td>$75.00</td>
<td>$74.8K</td>
<td>3</td>
<td align="right">0</td>
</tr>
<tr>
<td>OKTA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/17/27</td>
<td>$13.1</td>
<td>$11.9</td>
<td>$13.1</td>
<td>$80.00</td>
<td>$65.5K</td>
<td>13</td>
<td align="right">50</td>
</tr>
<tr>
<td>OKTA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$13.1</td>
<td>$13.0</td>
<td>$13.0</td>
<td>$100.00</td>
<td>$45.5K</td>
<td>1.1K</td>
<td align="right">48</td>
</tr>
<tr>
<td>OKTA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/06/25</td>
<td>$2.0</td>
<td>$1.9</td>
<td>$2.0</td>
<td>$105.00</td>
<td>$40.1K</td>
<td>1.4K</td>
<td align="right">216</td>
</tr>
</tbody>
</table>

<h3>About Okta</h3>
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
<h3>Present Market Standing of Okta</h3>
<ul>
<li>With a trading volume of 2,449,912, the price of OKTA is up by 0.03%, reaching $103.2.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 86 days from now.</li>
</ul>
<h3>Expert Opinions on Okta</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $137.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Buy rating on Okta with a target price of $150. 
&#x2A; Maintaining their stance, an analyst from Jefferies continues to hold a Hold rating for Okta, targeting a price of $130. 
&#x2A; An analyst from BMO Capital persists with their Market Perform rating on Okta, maintaining a target price of $135. 
&#x2A; An analyst from Guggenheim persists with their Buy rating on Okta, maintaining a target price of $140. 
&#x2A; Consistent in their evaluation, an analyst from Stifel keeps a Buy rating on Okta with a target price of $130. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Okta, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

OKTA

Market Whales and Their Recent Bets on OKTA Options

Analysts' ratings for Church &amp; Dwight Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHD#NYSE">CHD</a>) over the last quarter vary from bullish to bearish, as provided by 13 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Church &amp; Dwight Co, revealing an average target of $104.69, a high estimate of $125.00, and a low estimate of $84.00. Experiencing a 1.16% decline, the current average is now lower than the previous average price target of $105.92. 
<img src="https://www.benzinga.com/files/images/story/2025/1748887231_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Church &amp; Dwight Co. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nik Modi</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$114.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Dara Mohsenian</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$100.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Peter Grom</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$102.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$84.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Nik Modi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$100.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Javier Escalante</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$102.00</td>
<td>$106.00</td>
</tr>
<tr>
<td>Rupesh Parikh</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Peter Grom</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$110.00</td>
<td>$109.00</td>
</tr>
<tr>
<td>Anna Lizzul</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$125.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$94.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$98.00</td>
<td>$106.00</td>
</tr>
<tr>
<td>Chris Carey</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$97.00</td>
<td>$93.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Church &amp; Dwight Co. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Church &amp; Dwight Co compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Church &amp; Dwight Co's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Church &amp; Dwight Co's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CHD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Church &amp; Dwight Co analyst ratings.</a>
<h2>About Church &amp; Dwight Co</h2>
Church &amp; Dwight is the leading global producer of baking soda. Its portfolio extends beyond its legacy category to include laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm &amp; Hammer brand. Its mix also includes Batiste, OxiClean, Vitafusion, Hero, and TheraBreath, which together with Arm &amp; Hammer constitute around 70% of its annual sales and profits. Most recently, the firm announced the addition of Touchland, and its hand santizer business, to its fold. Even as it works to grow the reach of its products, Church &amp; Dwight still derives around 80% of its sales from its home market in the US.
<h3>Church &amp; Dwight Co: Financial Performance Dissected</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Church &amp; Dwight Co's revenue growth over a period of 3M has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately -2.41%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Staples sector.
Net Margin: Church &amp; Dwight Co's net margin is impressive, surpassing industry averages. With a net margin of 15.0%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Church &amp; Dwight Co's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 4.94%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Church &amp; Dwight Co's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 2.47%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.48, Church &amp; Dwight Co adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

13 Analysts Assess Church & Dwight Co: What You Need To Know

Morgan Stanley analyst Sanjit Singh maintains UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Equal-Weight and raises the price target from $12 to $15.

PATH

Morgan Stanley Maintains Equal-Weight on UiPath, Raises Price Target to $15

Murphy USA's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUSA#NYSE">MUSA</a>) short percent of float has risen 33.49% since its last report. The company recently reported that it has 1.16 million shares sold short, which is 8.37% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.46 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Murphy USA Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748887229_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Murphy USA has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Murphy USA's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Murphy USA's peer group average for short interest as a percentage of float is 10.12%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

MUSA

How Is The Market Feeling About Murphy USA?

SAP's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAP#NYSE">SAP</a>) short percent of float has fallen 31.58% since its last report. The company recently reported that it has 1.46 million shares sold short, which is 0.13% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.08 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>SAP Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748887224_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for SAP has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing SAP's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, SAP's peer group average for short interest as a percentage of float is 3.18%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

What's Driving the Market Sentiment Around SAP?

Cognizant Tech Solns's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTSH#NYSE">CTSH</a>) short percent of float has risen 22.22% since its last report. The company recently reported that it has 18.73 million shares sold short, which is 4.95% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.22 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Cognizant Tech Solns Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748887218_0_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Cognizant Tech Solns has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Cognizant Tech Solns's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Cognizant Tech Solns's peer group average for short interest as a percentage of float is 5.52%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

CTSH

What's Driving the Market Sentiment Around Cognizant Tech Solns?

In the current session, the stock is trading at $13.38, after a 1.52% increase. Over the past month, Chimera Investment Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIM#NYSE">CIM</a>) stock increased by 8.75%, and in the past year, by 10.59%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1748887218_0.png" alt="Past Year Chart" />

<h3>Evaluating Chimera Investment P/E in Comparison to Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Chimera Investment has a lower P/E than the aggregate P/E of 17.32 of the Mortgage Real Estate Investment Trusts (REITs) industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1748887218_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

P/E Ratio Insights for Chimera Investment

Press Releases

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN

Alumis and ACELYRIN Announce Amended Merger Agreement

ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis

Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote "FOR" the Proposed Transaction with Alumis

ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Alumis Stockholders Approve Merger with ACELYRIN

Earnings

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

Alumis Completes Merger with ACELYRIN

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

Comments

Alumis

Alumis (ALMS) Opciones

Alumis (NASDAQ:ALMS) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL